Drug General Information (ID: DDIHE2N17O)
Drug Name			Idelalisib		Drug Info		Mogamulizumab		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Pi3K Inhibitors				Antineoplastics

Mechanism of Idelalisib-Mogamulizumab Interaction (Severity Level: Moderate)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Idelalisib				Mogamulizumab
Mechanism		Diarrhea				Diarrhea
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Idelalisib and Mogamulizumab

Recommended Action
Management		Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.

References
1	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.